Cohort study demonstrates clinical activity in advanced cutaneous squamous cell carcinoma, supporting a new treatment strategy.
In a heavily pretreated real-life population with advanced cSCC, the anti-PD1/anti-EGFR combination showed clinical activity with acceptable safety, supporting its role as later-line strategy.
No takes yet. Share an insight, caveat, or question.
Guy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: